Sunday, May 23, 2021 1:34:33 AM
Agree, with the qualification that the approval for other cancers might come more quickly when considering the urgent need and the safety seen with dcvax unlike a lot of other cancer treatments.
The success against GBM that we expect and the promising results of the smaller trials applying dcvax against other cancers, and the successful treatment of that woman who told her story of having a very short life expectancy due to another terminal cancer and telling her story years later in apparently good health, these may bode well for quicker approvals.
Also more support for right to try especially when the treatment is so safe and side effect free, may also lead to earlier availability.
That said, there will be a ramp up in demand and with the Flaskworks technology I think additional capacity will be modularity achievable at much less costs than without.
You have to give nwbo credit for acquiring Flaskworks and it’s IP and founders at such a low cost vastly undervaluing its economic and strategic potential.
The success against GBM that we expect and the promising results of the smaller trials applying dcvax against other cancers, and the successful treatment of that woman who told her story of having a very short life expectancy due to another terminal cancer and telling her story years later in apparently good health, these may bode well for quicker approvals.
Also more support for right to try especially when the treatment is so safe and side effect free, may also lead to earlier availability.
That said, there will be a ramp up in demand and with the Flaskworks technology I think additional capacity will be modularity achievable at much less costs than without.
You have to give nwbo credit for acquiring Flaskworks and it’s IP and founders at such a low cost vastly undervaluing its economic and strategic potential.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
